
Opinion|Videos|June 21, 2024
Managing a Novel Therapeutic Option for mUC Treatment
Author(s)Pedro Barata, MD, MSc, FACP
A leading medical authority shares their hands-on experience with sacituzumab govitecan, focusing on the primary toxicity concerns, such as diarrhea and neutropenia, and outlining effective management strategies to mitigate these adverse effects and optimize patient care.
Advertisement
Episodes in this series

Describe your clinical experience with sacituzumabgovitecan - which patients, sequencing with other lines, major toxicity concerns (e.g. diarrhea, neutropenia) and management strategies.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5































